Valeo Pharma (TSE:VPH) Hits New 1-Year Low at $0.13

Valeo Pharma Inc. (TSE:VPH) reached a new 52-week low on Friday . The stock traded as low as C$0.13 and last traded at C$0.13, with a volume of 88571 shares trading hands. The stock had previously closed at C$0.16.

Valeo Pharma Stock Down 16.1 %

The firm has a market cap of C$12.83 million, a P/E ratio of -0.42 and a beta of 2.56. The business has a fifty day simple moving average of C$0.17 and a 200-day simple moving average of C$0.19.

Valeo Pharma (TSE:VPH) last issued its quarterly earnings results on Thursday, March 14th. The company reported C($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.08). The business had revenue of C$13.54 million for the quarter, compared to analysts’ expectations of C$15.30 million.

Valeo Pharma Company Profile

Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.